German CRO SocraTec R&D celebrates opening of new intensive monitoring clinical unit
By: SocraTec R&D GmbH
Head physicians and directors from the different departments of the Helios Klinikum followed SocraTec R&D's invitation to join the opening ceremony, get a tour through the new facilities and discuss clinical studies with the Scientific Directors and Investigators from SocraTec R&D. "The opening event was a great success and a good opportunity to set the SocraTec and Helios Teams up to a good start for our future collaboration.", said Dr. Barbara Schug, Managing Director and co-founder of SocraTec R&D.
The newly inaugurated intensive monitoring unit will mainly be used for early phase clinical trials in healthy volunteers and patients. These studies are the first step in clinical development of new medications, following successful pre-clinical development in the laboratory and animal studies. Dr. Frank Donath, SocraTec R&D's Medical Director stated: "Our new facilities are perfectly equipped for First-in-Human and Early-in-Patient trials which need a high level of safety surveillance."
Within the SocraTec R&D and Helios cooperation, SocraTec R&D will contribute with their scientific knowledge and more than 20 years of experience in clinical trials, while Helios will bring in their medical expertise in the fields of allergology, angiology, cardiology, dermatology, ear/nose/throat, gastroenterology, geriatrics, gynaecology, intensive care, nephrology, neuro-surgery, neurology, obstetrics, oncology, ophthalmology, oral and maxillofacial surgery, orthopaedics, paediatrics, pain, palliative care, psychiatry, pulmonology, rheumatology, spinal surgery, surgery, urology and vascular surgery.
And while this cooperation will not only be mutually beneficial for both companies, also the Helios's patients will be offered access to newly developed medication through the conducted studies.
SocraTec R&D's new intensive monitoring clinical unit complements their capacities and capabilities in the field of early phase clinical development, while their well-established main clinical pharmacology unit in the center of Erfurt will continue to cover later phases of clinical trials.
If you would like to read more about SocraTec R&D and their clinical research capabilities go to https://www.socratec-
SocraTec R&D GmbH
Dr. Maike Narten